Cargando…
Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects
[Image: see text] 7-Ethyl-10-hydroxycamptothecin (SN38) and vorinostat (SAHA) are quite promising combination therapy agents applied to the clinical treatment of cancer. In this study, we designed and synthesized a series of novel SN38-SAHA co-prodrugs, which were conjugated by four different amino...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964270/ https://www.ncbi.nlm.nih.gov/pubmed/31956782 http://dx.doi.org/10.1021/acsomega.9b02786 |
_version_ | 1783488453690785792 |
---|---|
author | Liu, Shuangxi Hu, Zonglong Zhang, Qiumeng Zhu, Qiwen Chen, Yi Lu, Wei |
author_facet | Liu, Shuangxi Hu, Zonglong Zhang, Qiumeng Zhu, Qiwen Chen, Yi Lu, Wei |
author_sort | Liu, Shuangxi |
collection | PubMed |
description | [Image: see text] 7-Ethyl-10-hydroxycamptothecin (SN38) and vorinostat (SAHA) are quite promising combination therapy agents applied to the clinical treatment of cancer. In this study, we designed and synthesized a series of novel SN38-SAHA co-prodrugs, which were conjugated by four different amino acids including glycine, alanine, aminobutyric acid, and 6-aminocaproic acid. The hydrolytic reconversion rate to SN38 and SAHA critically depended on the carbon chain length, which were evaluated in PBS (pH 6.0/7.4) and plasma (human/mouse). With decreasing amino acid chain length, the hydrolytic reconversion rate increased gradually. The in vitro cytotoxicity test was evaluated by the sulforhodamine B (SRB) assay on the human lung adenocarcinoma cell line A549 and human colorectal cancer cell line HCT116. With the evaluation of stability and in vitro cytotoxicity, an appropriate linker was found, and the active drug can be released efficiently from compound 3a, which exhibited strong antiproliferative activity in A549 and HCT-116 cell lines correspondingly. These results indicated that the well-designed co-prodrug 3a and this kind of strategy can be a promising approach for anticancer therapy. |
format | Online Article Text |
id | pubmed-6964270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-69642702020-01-17 Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects Liu, Shuangxi Hu, Zonglong Zhang, Qiumeng Zhu, Qiwen Chen, Yi Lu, Wei ACS Omega [Image: see text] 7-Ethyl-10-hydroxycamptothecin (SN38) and vorinostat (SAHA) are quite promising combination therapy agents applied to the clinical treatment of cancer. In this study, we designed and synthesized a series of novel SN38-SAHA co-prodrugs, which were conjugated by four different amino acids including glycine, alanine, aminobutyric acid, and 6-aminocaproic acid. The hydrolytic reconversion rate to SN38 and SAHA critically depended on the carbon chain length, which were evaluated in PBS (pH 6.0/7.4) and plasma (human/mouse). With decreasing amino acid chain length, the hydrolytic reconversion rate increased gradually. The in vitro cytotoxicity test was evaluated by the sulforhodamine B (SRB) assay on the human lung adenocarcinoma cell line A549 and human colorectal cancer cell line HCT116. With the evaluation of stability and in vitro cytotoxicity, an appropriate linker was found, and the active drug can be released efficiently from compound 3a, which exhibited strong antiproliferative activity in A549 and HCT-116 cell lines correspondingly. These results indicated that the well-designed co-prodrug 3a and this kind of strategy can be a promising approach for anticancer therapy. American Chemical Society 2019-12-23 /pmc/articles/PMC6964270/ /pubmed/31956782 http://dx.doi.org/10.1021/acsomega.9b02786 Text en Copyright © 2019 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. |
spellingShingle | Liu, Shuangxi Hu, Zonglong Zhang, Qiumeng Zhu, Qiwen Chen, Yi Lu, Wei Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects |
title | Co-Prodrugs of
7-Ethyl-10-hydroxycamptothecin
and Vorinostat with in Vitro Hydrolysis and Anticancer Effects |
title_full | Co-Prodrugs of
7-Ethyl-10-hydroxycamptothecin
and Vorinostat with in Vitro Hydrolysis and Anticancer Effects |
title_fullStr | Co-Prodrugs of
7-Ethyl-10-hydroxycamptothecin
and Vorinostat with in Vitro Hydrolysis and Anticancer Effects |
title_full_unstemmed | Co-Prodrugs of
7-Ethyl-10-hydroxycamptothecin
and Vorinostat with in Vitro Hydrolysis and Anticancer Effects |
title_short | Co-Prodrugs of
7-Ethyl-10-hydroxycamptothecin
and Vorinostat with in Vitro Hydrolysis and Anticancer Effects |
title_sort | co-prodrugs of
7-ethyl-10-hydroxycamptothecin
and vorinostat with in vitro hydrolysis and anticancer effects |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964270/ https://www.ncbi.nlm.nih.gov/pubmed/31956782 http://dx.doi.org/10.1021/acsomega.9b02786 |
work_keys_str_mv | AT liushuangxi coprodrugsof7ethyl10hydroxycamptothecinandvorinostatwithinvitrohydrolysisandanticancereffects AT huzonglong coprodrugsof7ethyl10hydroxycamptothecinandvorinostatwithinvitrohydrolysisandanticancereffects AT zhangqiumeng coprodrugsof7ethyl10hydroxycamptothecinandvorinostatwithinvitrohydrolysisandanticancereffects AT zhuqiwen coprodrugsof7ethyl10hydroxycamptothecinandvorinostatwithinvitrohydrolysisandanticancereffects AT chenyi coprodrugsof7ethyl10hydroxycamptothecinandvorinostatwithinvitrohydrolysisandanticancereffects AT luwei coprodrugsof7ethyl10hydroxycamptothecinandvorinostatwithinvitrohydrolysisandanticancereffects |